Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
Tamer Hellou, Advanced Hematology Clinical Fellowship at Mayo Clinic Rochester, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in American Journal of 0f Hematology, adding:
”Excited to share our newly published work in the American Journal of Hematology:
‘Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.’
In this study of 517 patients with newly diagnosed AL amyloidosis, +1q identified a distinct plasma cell–dominant phenotype, characterized by greater clonal burden and inferior long-term survival, while other high-risk cytogenetic lesions did not show the same adverse prognostic impact.
Importantly, despite good early hematologic and organ responses, patients with +1q remained at risk for poorer long-term outcomes, with its adverse impact becoming particularly evident beyond two years, highlighting the importance of long-term vigilance even in patients who respond well initially.
Grateful to Eli Muchtar and all my colleagues and collaborators at Mayo Clinic for their guidance and contributions to this work.”
Title: Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival
Authors: Tamer Hellou, Estefania Gauto Mariotti, Ahmed Alnughmush, Linda B. Baughn, Prashant Kapoor, Saurabh Zanwar, Shinichiro Suzuki, Maximilian J. Steinhardt, Daniel G. Packard, Taxiarchis V. Kourelis, Francis K. Buadi, David Dingli, Suzanne R. Hayman, Nelson Leung, Yi Lisa Hwa, Amie Fonder, Miriam Hobbs, Rahma Warsame, Joselle Cook, Moritz Binder, Nadine Abdallah, Yi Lin, Ronald S. Go, Robert A. Kyle, S. Vincent Rajkumar, Wilson I. Gonsalves, Shaji K. Kumar, Morie A. Gertz, Angela Dispenzieri, Eli Muchtar
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 13, 2026, 02:01Nour Al-Mozain: Is It Really Anti-D? – Unraveling Auto-Anti-LW in the Transfusion Laboratory
-
Oct 13, 2026, 01:51Berenice Villegas: The Role of Morphologic Evaluation in Body Fluid Differential Analysis
-
Oct 13, 2026, 01:44Debadrita Ray: Evaluating vWF and VITRO Score for Detecting CSPH in cACLD Patients
-
Oct 13, 2026, 01:34Nagesh Ramesh: Donating Blood for International Plasma Awareness Week
-
Oct 12, 2026, 21:51Sam Botchey: Orthobiologics Are Advancing but the Evidence Must Keep Pace
-
Oct 12, 2026, 21:50Serum Vitamin D, Platelet Function, and Bleeding in Primary ITP – Platelets Journal
-
Oct 12, 2026, 21:30Nika Samadzadeh Tabrizi: Looking Forward to the PACeS Trial on Anticoagulation for POAF
-
Oct 12, 2026, 21:28Michael Megaly: Does Coronary Ectasia Affect Outcomes in Acute Coronary Syndromes?
-
Oct 12, 2026, 21:25Vitor Borin P. de Souza: Think Twice Before Anticoagulating an Isolated Subsegmental PE